Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site

被引：1
|
作者：
Ribeiro, J. T. M. L.
Ali, S. M.
Correia, L.
Luis, I. M. V. D.
Matias, M.
Amaral, T.
Quintela, A. A. F. G.
Leitzel, K.
Lipton, A.
Costa, L.
机构：
[1] Hosp Santa Maria, Dept Oncol, Lisbon, Portugal
[2] Univ Lisbon, Inst Mol Med, P-1699 Lisbon, Portugal
[3] Lebanon VA Med Ctr, Penn State Hershey Med Ctr, Hershey, PA USA
[4] Hosp Santa Maria, Dept Pathol, Lisbon, Portugal
[5] Penn State Hershey Med Ctr, Hershey, PA USA
[6] Hosp Santa Maria, Dept Oncol, CHLN, Lisbon, Portugal
[7] IMM, Clin & Translat Oncol Res Unit, Lisbon, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11114
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [42] Can HER2 1+Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
    Shu, Lan
    Tong, Yiwei
    Li, Zhuoxuan
    Chen, Xiaosong
    Shen, Kunwei
    CANCERS, 2022, 14 (17)
  • [43] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [44] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04) : 535 - 540
  • [45] Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients
    Sasaki, Takahide
    Fuse, Nozomu
    Kuwata, Takeshi
    Nomura, Shogo
    Kaneko, Kazuhiro
    Doi, Toshihiko
    Yoshino, Takayuki
    Asano, Hiromichi
    Ochiai, Atsushi
    Komatsu, Yoshito
    Sakamoto, Naoya
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 43 - 48
  • [46] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [47] Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
    Punturi, Nindo B.
    Seker, Sinem
    Devarakonda, Vaishnavi
    Mazumder, Aloran
    Kalra, Rashi
    Chen, Ching Hui
    Li, Shunqiang
    Primeau, Tina
    Ellis, Matthew J.
    Kavuri, Shyam M.
    Haricharan, Svasti
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [48] Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
    Haricharan, Svasti
    Punturi, Nindo
    Seker, Sinem
    Devarakonda, Vaishnavi
    Kalra, Rashi
    Chen, Ching-Hui
    Mazumder, Aloran
    Li, Shungqiang
    Primeau, Tina
    Ellis, Matthew
    Kavuri, Shyam
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
    Burguin, Anna
    Furrer, Daniela
    Ouellette, Genevieve
    Jacob, Simon
    Diorio, Caroline
    Durocher, Francine
    PLOS ONE, 2020, 15 (06):
  • [50] A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
    Nathalie Reix
    Charlotte Malina
    Marie-Pierre Chenard
    Jean-Pierre Bellocq
    Stéphanie Delpous
    Sébastien Molière
    Anthony Sevrin
    Karl Neuberger
    Catherine Tomasetto
    Carole Mathelin
    Breast Cancer Research and Treatment, 2016, 160 : 249 - 259
12345